{"filing":{"accession_number":"0001193125-26-282855","cik":"0001806310","ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d121397d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526282855/d121397d8k.htm"},"events":[{"id":13932,"run_id":12383,"accession_number":"0001193125-26-282855","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Taysha entered into an underwriting agreement on June 24, 2026 to issue 32.5 million shares of common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per warrant in a registered public offering, with expected net proceeds of approximately $187.4 million (or $215.6 million with full exercise of the underwriters' 30-day option). The offering is expected to fund operations into the second half of 2028.","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11215,"accession_number":"0001193125-26-282855","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Taysha entered into an underwriting agreement on June 24, 2026 to issue 32.5 million shares of common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per warrant in a registered public offering, with expected net proceeds of approximately $187.4 million (or $215.6 million with full exercise of the underwriters' 30-day option). This is a material registered equity issuance that will dilute existing shareholders and is a primary capital-raising event for the clinical-stage biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:27:43.582908+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11216,"accession_number":"0001193125-26-282855","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Taysha announced the pricing of an underwritten public offering of 32.5 million shares of common stock at $6.00 per share and pre-funded warrants, with expected gross proceeds of approximately $200 million. This is a registered public offering of equity securities that will dilute existing shareholders. The company explicitly states it expects net proceeds to fund operations into the second half of 2028, indicating material capital needs and dilution to existing equity holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:27:43.582908+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11215,"accession_number":"0001193125-26-282855","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Taysha entered into an underwriting agreement on June 24, 2026 to issue 32.5 million shares of common stock at $6.00 per share and 833,333 pre-funded warrants at $5.999 per warrant in a registered public offering, with expected net proceeds of approximately $187.4 million (or $215.6 million with full exercise of the underwriters' 30-day option). This is a material registered equity issuance that will dilute existing shareholders and is a primary capital-raising event for the clinical-stage biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:27:43.582908+00:00","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-25"},{"id":11216,"accession_number":"0001193125-26-282855","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Taysha announced the pricing of an underwritten public offering of 32.5 million shares of common stock at $6.00 per share and pre-funded warrants, with expected gross proceeds of approximately $200 million. This is a registered public offering of equity securities that will dilute existing shareholders. The company explicitly states it expects net proceeds to fund operations into the second half of 2028, indicating material capital needs and dilution to existing equity holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:27:43.582908+00:00","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-25"}]}